GlassScriptPhysician profile
Norma B Talbo
NPI 1316097918
$1,379.59
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $190 · 2021: $13.06 · 2022: $37.17 · 2023: $579 · 2024: $15.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $594.26 | 2019-2023 | Austedo, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $353.49 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $123.50 | 2019-2024 | Invega Sustenna |
| Alkermes, INC. | $73.40 | 2019-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $71.49 | 2019-2020 | |
| Lundbeck LLC | $70.15 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $51.99 | 2019 | |
| Abbvie INC. | $41.31 | 2021-2023 | Vraylar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Talbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.